Anaptysbio (ANAB) Notes Payables (2017 - 2019)

Anaptysbio (ANAB) has 3 years of Notes Payables data on file, last reported at $1.4 million in Q4 2019.

• Quarterly Notes Payables fell 81.85% year-over-year to $1.4 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $1.4 million (down 81.85% YoY) and the FY2019 annual result came in at $1.4 million, down 81.85% from the prior year.
• Notes Payables eased to $1.4 million in Q4 2019, from $3.1 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $7.6 million in Q4 2018 to a low of $1.2 million in Q1 2017.
• A 3-year average of $5.2 million and a median of $5.7 million in 2017 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2018 — Notes Payables soared 500.0% — and 2019, when it sank 81.85%.
• Tracing ANAB's Notes Payables over 3 years: stood at $6.9 million in 2017, then grew by 10.17% to $7.6 million in 2018, then tumbled by 81.85% to $1.4 million in 2019.
• The last three Notes Payables figures came in at $1.4 million (Q4 2019), $3.1 million (Q3 2019), and $4.8 million (Q2 2019), per Business Quant data.